Christina Fanola, MD, MSC

Assistant Professor of Medicine, Cardiovascular Division

Christina Fanola

Contact Info

Office Phone 612-626-0919

Mailing Address:
MMC 508 420 Delaware St SE Minneapolis, MN 55455

Administrative Assistant Name

Administrative Email

Assistant Professor of Medicine, Cardiovascular Division

Cardiologist; Vascular Medicine Specialist

MD, George Washington School of Medicine, Washington, DC

K12 Career Development Fellowship Program in Vascular Medicine, Boston University Medical Center, Boston, MA

Fellowship in Cardiology, Boston University Medical Center, Boston, MA

Fellowship in Clinical Trials, TIMI Study Group, Harvard Medical School

MSc, Epidemiology, Boston University School of Public Health, Boston, MA

BA, International Affairs and Global Public Health, Early Selection PreMed Program, George Washington University, Washington DC


Dr. Fanola (formerly Cove) grew up in rural New Hampshire, and received both her bachelor’s and medical degrees through a combined undergraduate-medical school program at George Washington University in Washington, DC. At Boston University she completed her internal medicine residency and vascular medicine fellowship training, as well as research training through an NIH/NHLBI training grant, during which she also received her Masters of Science in epidemiology at Boston University School of Public Health. She then went on to complete cardiology fellowship training at Boston University and trained with the TIMI Study Group at Harvard Medical School and Brigham and Women’s Hospital in cardiovascular clinical trials.

Dr. Fanola is board certified in internal medicine, cardiovascular medicine, vascular medicine and vascular ultrasound (RPVI). Clinically she has an interest in the management of complex aortic and venous disease, and use of ultrasound in cardiac and vascular critical care. At Boston University she was co-instructor of a cardiac echocardiography and vascular ultrasound course under the Department of Medicine.

Research efforts have focused on antithrombotic drug agents and cardiovascular outcomes in vascular disease patients. While a trialist fellow at Harvard Medical School, she worked under the mentorship of Drs. Eugene Braunwald and Marc Sabatine and served as co-investigator for several cardiovascular drug trials, and developed a novel risk prediction model for patients on oral anticoagulation utilizing the ENGAGE AF – TIMI 48 trial database. She won an international Young Investigator Award in Thrombosis from the European Society of Cardiology in Rome, Italy for her work. In additional to clinical trials, her ongoing research interests include prediction models of poor outcomes for both pulmonary embolism and aortic disease patients, which bridge her research and clinical practices.


  • Noninvasive cardiology
  • Peripheral artery disease
  • Venous thromboembolism
  • Aortic disease
  • Vascular ultrasound
  • Echocardiography

Awards & Recognition

  • European Society of Cardiology: Young Investigator Award. August 2016
  • American College of Physicians: Young Leadership Award. June 2010

Professional Associations

  • American College of Cardiology
  • American Heart Association
  • Society of Vascular Medicine (Co-Chair, Next Generation Committee)
  • European Society of Cardiology
  • Pulmonary Embolism Response Team (PERT) Consortium
  • American Society of Echocardiography


Research Summary/Interests

  • Aortic disease
  • Pulmonary embolism
  • Peripheral artery disease
  • Antithrombotic drug therapy
  • Ultrasound
  • Noninvasive hemodynamics


  • Cove C, Albert C, Andreotti F, Gelder IC, Badimon L, Hylek EM. Female Sex as an Independent Risk Factor for Stroke in AF: Possible Mechanisms. Thromb Haemost. 2013 Dec 5;111(3).
  • Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc. 2013 Oct 23;2(5):e000136.
  • Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost. 2014 Feb 27;111(5). Fanola, CL. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vasc Health Risk Manag. 2015 May 27(11):271-82.
  • Fanola CL, Mooney D, Cowan AJ, Ko D, Henault L, Tripodis Y, Hylek EM. Incidence of severe renal dysfunction among individuals taking warfarin: potential implications for new oral anticoagulants. Am Heart J. 2017 Feb;184:150-155.
  • Fanola CL, Giugliano R, Trevisan M, Nordio F, Ruff C, Antman E, Braunwald E. A novel risk score for a net clinical outcome in atrial fibrillation from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J.2017;12:888-896.
  • Christina L. Fanola, MD, ScM, David A. Morrow MD MPH, Christopher P. Cannon MD, Mary Ann Lukas MD, Erica L. Goodrich MS, Eugene Braunwald MD, Michelle L. O’Donoghue MD MPH. Interleukin-6 and the Risk of Adverse Outcomes in Patients after an Acute Coronary Syndrome: Observations from the SOLID-TIMI 52 Trial. J Am Heart Assoc. 2017Oct 24;6(10).
  • Christina Fanola, Christian Ruff, Sabina Murphy, James Jin, Anil Duggal, Michele Mercuri, Elliott Antman, Eugene Braunwald and Robert Giugliano. Efficacy and Safety of Edoxaban in Patients with Atrial Fibrillation and Malignancy: Analysis of the ENGAGE AF – TIMI 48 Trial (JAHA, under revision).
  • Brian Bergmark, Deepak Bhatt, Philippe Steg, Christina Fanola, Ofri Mosenzon, Itamar Raz, Eugene Braunwald, Benjamin Scirica. Blood pressure, subclinical myocardial injury and cardiovascular outcomes among patients with diabetes and high cardiovascular risk: Observations from the SAVOR – TIMI 53 Trial. European Heart Journal. 2018 Jan 31. Epub ahead of print.
  • Bohula EA1, Scirica BM2, Fanola C2, Inzucchi SE3, Keech A4, McGuire DK5, Smith SR6, Abrahamsen T2, Francis BH7, Miao W7, Perdomo CA7, Satlin A7, Wiviott SD2, Sabatine MS2.Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. Am Heart J. 2018 Mar 29;202:39-48. doi: 10.1016/j.ahj.2018.03.012. Epub ahead of print.
  • T.F. Chao S.A. Chen M.F. Fanola C.L. Mercuri C.T. RuffR.A. Hamershock E.M. Antman E. Braunwald R.P. Giugliano. The usefulness of the TIMI-AF score in the prediction of ischemic stroke and bleeding for Asian patients with atrial fibrillation. European Heart Journal, Volume 38, Issue suppl_1, 1 August 2017, ehx504.P3605.


Academic Interests and Focus

cardiac and vascular ultrasound, acute aortic syndromes, high risk pulmonary embolism


Board Certifications

  • Internal Medicine
  • Cardiovascular Medicine
  • Vascular Medicine
  • Vascular Ultrasound (RPVI)
  • Echocardiography

Clinical Interests

Noninvasive cardiology; Aortic Disease; Pulmonary Embolism; Peripheral artery disease; Echocardiography and Vascular Ultrasound

Hospital Privileges

University of Minnesota Medical Center, Fairview